The seed was planted when Hubbard stumbled upon a Substack column by Julia Christina in 2021. The newsletter, called The Journey, has just over a
Earlier this year, we published a deep dive into Terran Biosciences’ apparent intellectual property strategy. We concluded by asking a question: One might also ask
This November, promising developments emerged across various areas of psychedelic research. To start, an innovative study explored novel routes of administering ayahuasca-analogue compounds, potentially improving
*** November’s meeting of the full Natural Medicine Advisory Board began with a brief administrative update from recently-appointed program director Lorey Bratten, mostly around new
The American College of Neuropsychopharmacology (ACNP) held its 62nd annual meeting in Florida from the 3rd – 6th of December. For the past few years, psychedelics and
The natural question arising is: when might we expect to hear about a decision from the FDA? The answer—perhaps unsurprisingly—is that it’s complicated If the
Given that drugs placed in Schedule I of the Controlled Substances Act (CSA) are deemed (among other things) to have “no accepted medical use”, one
This Issue of the Bulletin primarily focuses on psychedelic drug development and business stories, with around 4,000 words of coverage and analysis. Featured content in
While national phase entries for Compass’s WO2023114097 PCT are not due until June 2024 (30 months from the priority date), all claims relating to co-use
In last week’s policy-focused Bulletin (149) we covered the publication of Transform Drug Policy Foundation’s 124-page guide, How to Regulate Psychedelics. Shortly after its publication,